The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine. • By Product, the consumables accounted for the largest share of the in vivo toxicology market.
The in vivo toxicology market is categorized into instruments and consumables.The consumables segment is further categorized into animal models and reagents & kits.
Animal models is sub segmented into mice, rat and other animals.The consumables segment accounted for the largest share of the in vivo toxicology market in 2019.
The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment.
By toxicity endpoint, the immunotoxicity segment accounted for the largest share of the in vivo toxicology market.
The global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment
By test type, chronic test type segment accounted for the largest share of the in vivo toxicology market The global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic test type.The chronic test type segment is expected to dominate the market during the forecast period.
In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.
By End user, Academic and Research Institutes accounted for the largest share of the in vivo toxicology market The global in vivo toxicology market has been broadly segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users (cosmetic companies and food laboratories). The academic and research institutes segment accounted for the largest share of the in vivo toxicology market in 2019. The increasing number of research activities in the field of in vivo toxicology and funding to the academic and research institutes to conduct in vivo toxicology research are the factors responsible for the largest share of the segment Asia Pacific: The fastest-growing region in the in vivo toxicology market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region.
A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.
North America: The largest share of the in vivo toxicology market.
North America, which includes the US and Canada, accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: • By Respondent– Supply Side- 80%, Demand Side-20% • By Designation— Executives- 25%, CXOs- 20%, Managers - 55% • By Region— North America - 50%, Europe - 20%, APAC – 20%, RoW- 10%
The in vivo toxicology market is dominated by a few globally established players such as Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia),and Harbour BioMed (US)
Research Coverage: The report segments the in vivo toxicology market based on region (North America, Asia Pacific, Europe, Latin America and Middle East & Africa), product (instruments, consumables((Animal models (mice, rat and other animal odels), Reagents & kits)) test type (acute, sub-acute, sub-chronic, and chronic ) , Testing facility (outsourced and in-house), toxicity end point (immunotoxicity, systemic toxicity, carcinogenicity, end user(academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users).Company type (Tier 1, tier 2, Tier 3 providers of in vivo toxicology instruments and services).
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the in vivo toxicology market.
Key Benefits of Buying the Report: The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.
The report also helps stakeholders understand the pulse of the in vivo toxicology market and provides them information on key market drivers, challenges, and opportunities.
Our reports have been used by over 10K customers, including:
The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period. The increasing expenditure by pharmaceutical companies, alongside rising government spending is leading has driven the pace of R&D activity in this industry to develop new drugs. This...
The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027. MARKET INSIGHTS Live cell imaging is one of the popular techniques for studying live cells and investigating the biological processes in real-time. It utilizes time-lapse microscopy and careful preparation of living cell...
INTRODUCTION It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry. The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved....
The Live Cell Imaging market is projected to register a CAGR of 7.37% during the forecast period with market size of USD 1,802.18 million in 2021 and expected to reach USD 2,775.88 million by 2027. The COVID-19 pandemic had a severe impact on the market as there were supply chain disruptions due to lockdown. However, the increasing...
The research antibodies and reagents market is projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market evolved owing to factors such as increasing proteomics and genomics research, growing demand for antibodies for research reproducibility,...
The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this...
The mice model market is expected to grow from US$ 1,705.70 million in 2022 to US$ 2,340.90 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028. The growing usage of mice models in virology and infectious diseases and the rising consumption of personalized medicine are bolstering the growth of the mice model...
The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3billion in 2022, at a CAGR of 7.9% during the forecast period. The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging...
Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products.Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services...
200 pages •
By Roots Analysis Private Ltd.
• Jun 2022
INTRODUCTION The oral solid dosage (OSD) market is the largest segment in the pharmaceutical industry, anticipated to reach over USD 900 billion by 2027. However, one of key concerns associated with this industry is that the active pharmaceutical ingredients (APIs) used in orally administered dosage forms inherently possess...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.